Cargando…

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study

AIM: To assess the efficacy and safety of latanoprostene bunod (LBN) compared with latanoprost 0.005%, and to determine the optimum drug concentration(s) of LBN in reducing intraocular pressure (IOP) in subjects with open angle glaucoma or ocular hypertension. METHODS: Randomised, investigator-maske...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weinreb, Robert N, Ong, Tuyen, Scassellati Sforzolini, Baldo, Vittitow, Jason L, Singh, Kuldev, Kaufman, Paul L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453588/ https://www.ncbi.nlm.nih.gov/pubmed/25488946 http://dx.doi.org/10.1136/bjophthalmol-2014-305908

Ejemplares similares

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects
por: Araie, Makoto, et al.
Publicado: (2015)

Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
por: Kawase, Kazuhide, et al.
Publicado: (2016)

Critical evaluation of latanoprostene bunod in the treatment of glaucoma
por: Garcia, Giancarlo A, et al.
Publicado: (2016)

Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma
por: Zhou, Benjamin, et al.
Publicado: (2022)

Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis
por: Lo, Tzu-Chen, et al.
Publicado: (2022)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue, Kenji, et al.
Publicado: (2012)

Noninferiority Study Comparing Latanoprost 0.005% Without Versus With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension
por: Wirta, David, et al.
Publicado: (2022)

Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
por: Wang, Yulong, et al.
Publicado: (2020)

Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open‐angle glaucoma and ocular hypertension
por: Fingeret, Murray, et al.
Publicado: (2019)

Open-Label Extension Study Comparing Latanoprost 0.005% Without vs With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension
por: Shen Lee, Bridgitte, et al.
Publicado: (2022)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Nakakura, Shunsuke, et al.
Publicado: (2012)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: Godfrey, David A, et al.
Publicado: (2009)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis, Victoria M, et al.
Publicado: (2018)

Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
por: Harasymowycz, Paul, et al.
Publicado: (2022)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Özkurt, Yelda Buyru, et al.
Publicado: (2009)

Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan(®) and Arulatan(®)) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial
por: Brant Fernandes, Rodrigo A, et al.
Publicado: (2019)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
por: Paolera, Mauricio D, et al.
Publicado: (2008)

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
por: Radcliffe, Nathan, et al.
Publicado: (2020)

Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma
por: Okeke, Constance O., et al.
Publicado: (2020)

The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
por: Cavet, Megan E., et al.
Publicado: (2018)

A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study
por: Walters, Thomas R., et al.
Publicado: (2022)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma
por: Hagras, Sherein M, et al.
Publicado: (2021)

Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride
por: Wong, Tina T, et al.
Publicado: (2018)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
por: Inoue, Kenji, et al.
Publicado: (2012)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
por: Inoue, Kenji, et al.
Publicado: (2014)

Intraocular Pressure Reduction Effect of 0.005% Latanoprost Eye Drops in a Hyaluronic Acid-Chitosan Nanoparticle Drug Delivery System in Albino Rabbits
por: Rubenicia, Ana Marie L., et al.
Publicado: (2021)

An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (w/v) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
por: Freiberg, Josefine C., et al.
Publicado: (2022)

Retract p < 0.005 and propose using JASP, instead
por: Perezgonzalez, Jose D., et al.
Publicado: (2018)

Reply to Hall J: “Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population”: Virender S. Sangwan, P. Andrew Pearson, Hemanth Paul, Timothy L. Comstock
por: Scassellati Sforzolini, Baldo
Publicado: (2015)

The assessment of intrinsic credibility and a new argument for p < 0.005
por: Held, Leonhard
Publicado: (2019)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2012)

Early Effect of 0.005% Estriol Vaginal Gel on Symptoms and Signs of Vulvovaginal Atrophy
por: Lázaro-Carrasco de la Fuente, Jesús, et al.
Publicado: (2022)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
por: Pacella, Fernanda, et al.
Publicado: (2012)

Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
por: Molinelli, Elisa, et al.
Publicado: (2020)

Latanoprost in the treatment of glaucoma
por: Alm, Albert
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6s4pib42i6th5nhghnq1jungnf